Intralesional injection of herpes simplex virus 1716 in metastatic melanoma
- 1 February 2001
- journal article
- Published by Elsevier in The Lancet
- Vol. 357 (9255) , 525-526
- https://doi.org/10.1016/s0140-6736(00)04048-4
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaGene Therapy, 2000
- Treatment of Experimental Subcutaneous Human Melanoma with a Replication-Restricted Herpes Simplex Virus MutantJournal of Investigative Dermatology, 1997
- Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2Journal of General Virology, 1994
- Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequenceJournal of General Virology, 1991